Crestone, Inc
Crestone is a Boulder, Colorado based clinical stage biopharmaceutical company dedicated to developing novel drugs with entirely new mechanisms to treat serious bacterial infections, including C. difficile, antibiotic-resistant Gram-positive infections, tuberculosis, and more. The company focuses on inventing and researching small molecule drugs to combat antimicrobial resistance and improve public health.
Industries
Nr. of Employees
small (1-50)
Products
MetRS-targeting small-molecule for C. difficile (clinical-stage)
A narrow-spectrum oral small-molecule protein synthesis inhibitor that targets methionyl-tRNA synthetase to treat Clostridioides difficile infection; developed to minimize disruption of normal intestinal microbiota and to reduce toxin production and sporulation.
Gram-positive antibacterial candidate evaluated in hollow-fiber model
A small-molecule antibacterial candidate advanced through hollow-fiber system modeling to assess efficacy against Gram-positive pathogens in preclinical pharmacodynamic studies.
Benzothiazole-amide MmpL3 inhibitor for NTM/TB (preclinical)
A preclinical anti-mycobacterial program focused on benzothiazole-amide compounds that inhibit the MmpL3 protein essential for mycobacterial cell-wall synthesis, showing potency against nontuberculous mycobacteria and multidrug-resistant strains.
MetRS-targeting small-molecule for C. difficile (clinical-stage)
A narrow-spectrum oral small-molecule protein synthesis inhibitor that targets methionyl-tRNA synthetase to treat Clostridioides difficile infection; developed to minimize disruption of normal intestinal microbiota and to reduce toxin production and sporulation.
Gram-positive antibacterial candidate evaluated in hollow-fiber model
A small-molecule antibacterial candidate advanced through hollow-fiber system modeling to assess efficacy against Gram-positive pathogens in preclinical pharmacodynamic studies.
Benzothiazole-amide MmpL3 inhibitor for NTM/TB (preclinical)
A preclinical anti-mycobacterial program focused on benzothiazole-amide compounds that inhibit the MmpL3 protein essential for mycobacterial cell-wall synthesis, showing potency against nontuberculous mycobacteria and multidrug-resistant strains.
Services
Sponsor-managed multicenter clinical trials
Sponsorship and coordination of Phase 1–2 multicenter clinical studies including site selection, enrollment, and data collection for infectious-disease drug candidates.
Sponsor-managed multicenter clinical trials
Sponsorship and coordination of Phase 1–2 multicenter clinical studies including site selection, enrollment, and data collection for infectious-disease drug candidates.
Expertise Areas
- Clinical trial management
- Small-molecule antibacterial discovery
- Antimicrobial resistance research
- Medicinal and process chemistry
Key Technologies
- Targeted small-molecule inhibitors of methionyl-tRNA synthetase
- MmpL3-targeting anti-mycobacterial compounds
- Hollow-fiber infection model
- In vivo pharmacodynamic models